Cure8 research brief
Perianal fistulizing Crohn's disease is difficult to treat and many patients have failed anti-TNF therapy. Evidence that ustekinumab achieves high clinical fistula response and remission rates in a real-world multicenter cohort could influence treatment choices and discussions about expected outcomes.
Adult Crohn's patients with perianal fistulas, clinicians who manage complex perianal Crohn's disease, and researchers studying medical and surgical approaches to fistulizing disease.
This paper pooled real-world data from 163 patients treated with UST between 2020–2023 and reports improvements in inflammatory blood markers (CRP, ESR) and hemoglobin. Clinical response and remission rates reported are based on the study's clinical definitions; objective MRI-confirmed fistula healing was much lower than clinical response rates.
The authors performed multivariate analyses to identify independent predictors of healing and built a predictive nomogram (AUC 0.852 for 24-week remission) intended to help individualize treatment decisions.
Safety signals were limited in this cohort (adverse event rate 7.4%) and no severe safety issues were reported in the abstracted data, but retrospective design and follow-up length are important to consider.
This is a retrospective multicenter study (2020–2023) with median 15-month follow-up and an abstract-level structured summary. MRI-confirmed healing was much lower than clinical remission, and retrospective designs can include selection and measurement biases. The nomogram requires external validation before routine clinical use.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Patients considering switching biologics or clinicians choosing a second‑line therapy may care because the study suggests ustekinumab had better long‑term persistence and improving remission rates compared with anti‑TNF...
Perianal fistulas are a serious complication of Crohn’s disease with limited high-quality trial evidence. This randomized trial suggests ustekinumab may increase the chance of combined clinical and MRI remission at 12...
For people with moderate–severe Crohn’s disease who failed anti‑TNF drugs, this trial suggests risankizumab may achieve higher corticosteroid‑free clinical and endoscopic remission than ustekinumab, which could mean...
